These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 3917270

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
    Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Liuzzi A, Chiodini PG.
    J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
    [Abstract] [Full Text] [Related]

  • 3. The higher the growth hormone response to growth hormone releasing hormone the lower the response to bromocriptine and thyrotrophin releasing hormone in acromegaly.
    Smals AE, Pieters GF, Smals AG, Hermus AR, Benraad TJ, Kloppenborg PW.
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):43-7. PubMed ID: 3115634
    [Abstract] [Full Text] [Related]

  • 4. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW, Klijn JG, van Vroonhoven CC, Stefanko SZ.
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [Abstract] [Full Text] [Related]

  • 5. Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
    Watanobe H, Tamura T, Sasaki S, Takebe K.
    Neuropeptides; 1993 Dec; 25(6):363-75. PubMed ID: 8127416
    [Abstract] [Full Text] [Related]

  • 6. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G, Petroncini MM, Dallabonzana D, Cozzi R, Verde G, Chiodini PG, Liuzzi A.
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [Abstract] [Full Text] [Related]

  • 7. Effects of human pancreatic tumor growth hormone-releasing hormone (hpGRH1-44-NH2) on immunoreactive and bioactive plasma growth hormone in normal young men.
    Sassolas G, Chatelain P, Cohen R, Boissel JP, Laporte S, Galleyrand J, Claustrat B, Elmcharfi A, Chayvialle JA, Cohen H.
    J Clin Endocrinol Metab; 1984 Oct; 59(4):705-9. PubMed ID: 6148353
    [Abstract] [Full Text] [Related]

  • 8. Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly.
    Ishibashi M, Yamaji T.
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1251-6. PubMed ID: 122426
    [Abstract] [Full Text] [Related]

  • 9. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C.
    Moses AC, Molitch ME, Sawin CT, Jackson IM, Biller BJ, Furlanetto R, Reichlin S.
    J Clin Endocrinol Metab; 1981 Oct; 53(4):752-8. PubMed ID: 6793607
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Growth hormone and prolactin responses to bolus and sustained infusions of GRH-1-40-OH in man.
    Goldman JA, Molitch ME, Thorner MO, Vale W, Rivier J, Reichlin S.
    J Endocrinol Invest; 1987 Aug; 10(4):397-406. PubMed ID: 3119697
    [Abstract] [Full Text] [Related]

  • 12. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M, Yamaji T.
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [Abstract] [Full Text] [Related]

  • 13. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.
    Ishibashi M, Yamaji T.
    J Clin Endocrinol Metab; 1985 May; 60(5):985-93. PubMed ID: 2858494
    [Abstract] [Full Text] [Related]

  • 14. Growth hormone responses to the releasing hormones GHRH and GnRH and the inhibitors somatostatin and bromocriptine in TRH-responsive and non-responsive acromegalics.
    Smals AE, Pieters GF, Smals AG, Hermus AR, Benraad TJ, Kloppenborg PW.
    Acta Endocrinol (Copenh); 1987 Sep; 116(1):53-8. PubMed ID: 2889308
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [The relationship between TSH response to TRH and GH response to dopaminergic agents in patients with acromegaly].
    Tokuyama T, Yoshinari M, Okamura K, Ikenoue H, Sato K, Kuroda T, Fujishima M.
    Nihon Naibunpi Gakkai Zasshi; 1991 Feb 20; 67(2):65-74. PubMed ID: 1674920
    [Abstract] [Full Text] [Related]

  • 20. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.
    Losa M, Schopohl J, König A, Müller OA, von Werder K.
    J Clin Endocrinol Metab; 1986 Aug 20; 63(2):475-80. PubMed ID: 3088026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.